On October 22, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, reported the release of a new Virtual Investor "What This Means" segment highlighting the Company’s progress advancing ERNA-101 toward the clinic and the scientific foundation supporting its broader cell therapy platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The discussion brings together Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, a member of Ernexa’s Scientific Advisory Board and developer of the technology underlying the Company’s platform; and Dr. Robert Pierce, Chief Scientific Officer, to discuss three key areas central to Ernexa’s next phase of development: regulatory alignment, scientific differentiation and progress toward first-in-human clinical evaluation.
At the center of the conversation is Ernexa’s pre-IND interaction with the U.S. Food and Drug Administration and what that milestone means for ERNA-101’s advancement in ovarian cancer. Mr. Luther discusses the strategic importance of the meeting, while Dr. Pierce provides additional perspective on the FDA feedback and its implications for the scientific and clinical development program.
"ERNA-101 is moving through a critical transition from preclinical development toward the clinic, and our focus is on executing each step with discipline," said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. "The progress we are making across regulatory planning, IND-enabling development and clinical preparation is bringing us closer to the point where we can begin evaluating this technology in patients."
The segment also provides a deeper look at the technology underlying Ernexa’s platform. Dr. Rohde discusses why induced mesenchymal stromal cells were selected as the foundation of the platform, the potential advantages of an allogeneic, off-the-shelf approach and the rationale for engineering ERNA-101 to express IL-7 and IL-15 within the tumor microenvironment.
"Our goal from the beginning was to build a cell therapy platform that could combine the flexibility of cellular engineering with an approach designed for practical, off-the-shelf use," said Dr. Rohde. "ERNA-101 reflects that strategy by pairing an engineered cell platform with immune-modulating biology intended to act where it matters most, within the tumor microenvironment."
Dr. Pierce further discusses how this underlying biology translates into Ernexa’s preclinical findings, including the program’s potential to recruit immune cells, alter the tumor microenvironment and enhance checkpoint blockade. The conversation also addresses findings from IND-enabling studies related to safety, biodistribution and tumor-homing characteristics as the Company prepares ERNA-101 for clinical development.
"The importance of the platform is not simply what it is engineered to do, but whether the biology translates into meaningful and reproducible activity," said Dr. Robert Pierce, Chief Scientific Officer of Ernexa Therapeutics. "Our preclinical work is helping us understand that biology in greater depth and build the scientific package needed to support ERNA-101’s advancement into the clinic."
Looking ahead, the segment outlines what investors can expect between Ernexa’s FDA interaction and initiation of a first-in-human clinical study. The discussion also explores how the underlying technology could potentially be adapted beyond the lead ovarian cancer program across additional solid tumors and therapeutic approaches.
"We believe ERNA-101 represents more than a single development program," added Mr. Luther. "Our immediate priority is to advance the asset into the clinic, but the broader opportunity lies in demonstrating what this platform can potentially enable across oncology. That is the value we are working to unlock."
(Press release, Ernexa Therapeutics, OCT 22, 2026, View Source [SID1234673692])